Mirna’s lead product candidate, MRX34, is the first microRNA mimic to enter clinical development in oncology. MRX34 is being studied as a single agent in our ongoing open-label, multicenter Phase 1 clinical trial, which has included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013.
Closing share price